Apellis Pharmaceuticals, Inc. (APLS) Q4 2025 Earnings Call Transcript

Apellis Pharmaceuticals, Inc. (APLS) Q4 2025 Earnings Call Transcript

Seeking Alpha • 9 hours ago

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its fourth quarter and full year 2025 financial results and business highlights.

GlobeNewsWire • 13 hours ago

Apellis Pharmaceuticals (APLS) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for Apellis Pharmaceuticals (APLS) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research • 8 hours ago

Apellis Pharmaceuticals, Inc. (APLS) Surpasses Q4 Earnings and Revenue Estimates

Apellis Pharmaceuticals, Inc. (APLS) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of a loss of $0.4 per share. This compares to a loss of $0.29 per share a year ago.

Zacks Investment Research • 8 hours ago

Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference

WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will participate in a webcast fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, at 9:50 a.m. ET.

GlobeNewsWire • Feb 23, 2026

Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting

Company will debut five-year results from GALE study showing meaningful impact of early and continuous treatment with SYFOVRE ® (pegcetacoplan injection) WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that eight abstracts were accepted for oral presentations at the 49th Macula Society Annual Meeting, taking place February 25-28 in San Diego, California.

GlobeNewsWire • Feb 19, 2026

Earnings Preview: Apellis Pharmaceuticals, Inc. (APLS) Q4 Earnings Expected to Decline

Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Feb 17, 2026

Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results

WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026 at 8:30 a.m. ET.

GlobeNewsWire • Feb 10, 2026

5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates

Let us look at some drug/biotech stocks, ZTS, PCRX, APLS, ACAD and DNLI, which are poised to beat on fourth-quarter 2025 earnings.

Zacks Investment Research • Feb 3, 2026

Apellis Pharmaceuticals (APLS) Surges 5.8%: Is This an Indication of Further Gains?

Apellis Pharmaceuticals (APLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Investment Research • Jan 29, 2026